{"id": "batch_req_680141fb23d48190838745389c5c87ef", "custom_id": "alendronic acid-Lamivudine-Metoprolol-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "e67fac7b1f05e44525fef2e47bb9a6c9", "body": {"id": "chatcmpl-BNNpX5fDLlacG0QXGgQgK6tDWI9tS", "object": "chat.completion", "created": 1744912847, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient being treated with a nucleoside reverse transcriptase inhibitor for chronic hepatitis B and HIV exhibits signs of difficulty in articulating speech after being prescribed an additional medication that acts as a cardioselective \u03b21-adrenergic receptor antagonist commonly used in the management of hypertension and angina. Based on the known drug interaction characterized by the emergence of dysarthria, which medication is most likely responsible for this side effect when combined with the antiviral agent?\n\nAnswer: Metoprolol", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 908, "completion_tokens": 100, "total_tokens": 1008, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fb37c08190ab2f894954f5ccff", "custom_id": "Ketoprofen-Lamivudine-Metoprolol-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "ca108f2093cb96375f9adac3ee16b43e", "body": {"id": "chatcmpl-BNNpZbtsjCZ2eyddRClJij5mfj7kY", "object": "chat.completion", "created": 1744912849, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient taking an antiretroviral nucleoside reverse transcriptase inhibitor known for treating HIV and hepatitis B\u2014who reports side effects such as hepatotoxicity or lactic acidosis\u2014develops dysarthria after starting a new medication used primarily as a selective beta1-blocker for angina, hypertension, and post-myocardial infarction care. Based on drug-drug interaction knowledge, which medication was newly added to the regimen?\n\nAnswer: Metoprolol", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 798, "completion_tokens": 98, "total_tokens": 896, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fb56408190b249ff256d700cff", "custom_id": "alendronic acid-Efavirenz-oxybutynin-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "0394263e6ae345e2c8cdcaabedc5f144", "body": {"id": "chatcmpl-BNNpbvWmIkopty3Rfc8Ir7ucIrM9h", "object": "chat.completion", "created": 1744912851, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA bisphosphonate used for osteoporosis can cause adenopathy when combined with a non-nucleoside reverse transcriptase inhibitor that is a cornerstone in HIV regimens. This antiretroviral agent, when taken together with which potent antimuscarinic therapy for overactive bladder, can lead to constipation as an interaction outcome?\n\nAnswer: oxybutynin", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 937, "completion_tokens": 75, "total_tokens": 1012, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fb6c9c8190832a332fd9353603", "custom_id": "Carvedilol-Efavirenz-Lamivudine-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "d52cf2738dd6cd3e6b731cab13289a3c", "body": {"id": "chatcmpl-BNNpcllunsHwdvNn2qBTvMiMFUD8q", "object": "chat.completion", "created": 1744912852, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA nonselective beta-blocker used in chronic heart failure treatment may interact with a non-nucleoside reverse transcriptase inhibitor applied in HIV management to cause high blood pressure. When this reverse transcriptase inhibitor is further combined with a nucleoside reverse transcriptase inhibitor indicated for both HIV and chronic hepatitis B, commonly co-administered with zidovudine and considered safe during pregnancy, the interaction may result in gastric inflammation. Based on these relationships, which drug is involved in causing gastric inflammation when combined with the non-nucleoside reverse transcriptase inhibitor?\n\nAnswer: Lamivudine", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 956, "completion_tokens": 123, "total_tokens": 1079, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fb830481908a96994759249d03", "custom_id": "Norfloxacin-Zolpidem-vincristine-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "4940d4a1c35575bebf7d0f3e2450146c", "body": {"id": "chatcmpl-BNNpetmP4nMAFjmW4OAN5OjCeoXTt", "object": "chat.completion", "created": 1744912854, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient taking a nonbenzodiazepine hypnotic with a Schedule IV designation for insomnia develops adenopathy after starting a second drug. This second drug is a vinca alkaloid derived from Catharanthus roseus, clinically used in the treatment of acute leukemias and Hodgkin's lymphoma through mitotic inhibition. Which drug, when combined with the hypnotic, can lead to this adverse lymph node-related effect?\n\nAnswer: vincristine", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 946, "completion_tokens": 93, "total_tokens": 1039, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fb95c48190972b6863b021b6c7", "custom_id": "Metolazone-Pamidronic acid-thiotepa-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "17bb2fe231bb29f91be41319530d9c33", "body": {"id": "chatcmpl-BNNpfnTfGG5FPcyY1cx5G7hB1R8HJ", "object": "chat.completion", "created": 1744912855, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA nitrogen-containing bisphosphonate used to prevent osteoporosis can interact with an anti-cancer medication that is an organophosphorus compound to cause erythema. Which anti-cancer medication is this?\n\nAnswer: thiotepa", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 568, "completion_tokens": 49, "total_tokens": 617, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fbafa88190a40eb2f6b7c6072d", "custom_id": "Ketorolac-Ondansetron-Trazodone-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "45232557a514b094885dd2abc83b3665", "body": {"id": "chatcmpl-BNNpgsYA9ef2B2cK8la3ECxrUHWwy", "object": "chat.completion", "created": 1744912856, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nWhich medication, classified as a serotonin antagonist and reuptake inhibitor used for depressive and anxiety disorders as well as insomnia, is known to potentially contribute to the development of hepatic neoplasia when co-administered with an antiemetic that antagonizes 5-HT3 receptors and is commonly prescribed for chemotherapy-induced nausea and vomiting?\n\nAnswer: Trazodone", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 987, "completion_tokens": 76, "total_tokens": 1063, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680141fbc56081908a2ecc49fc9db91e", "custom_id": "Oxaprozin-Sildenafil-Zaleplon-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "196b6c97a1f4604337c3dd42ac763812", "body": {"id": "chatcmpl-BNNpi6OK3pQge7eMCgxntMDBfqDJX", "object": "chat.completion", "created": 1744912858, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient is prescribed a nonbenzodiazepine sedative-hypnotic from the pyrazolopyrimidine class for insomnia. According to known drug-drug interaction data, when this insomnia medication is taken alongside a selective phosphodiesterase type 5 inhibitor used for erectile dysfunction and pulmonary arterial hypertension, there is an increased risk of apoplexy. Which drug is the patient most likely taking for insomnia in this scenario?\n\nAnswer: Zaleplon", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 711, "completion_tokens": 96, "total_tokens": 807, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fbd8ac81908a07b9e80d28cf5a", "custom_id": "Ketorolac-Duloxetine-desvenlafaxine-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "0606273fe19dd5c67279950d74c1f245", "body": {"id": "chatcmpl-BNNpjB8whrtLnbrUxtOeGvKCPpZQX", "object": "chat.completion", "created": 1744912859, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient managing major depressive disorder with a serotonin\u2013norepinephrine reuptake inhibitor, who experiences adenopathy as a result of combining this medication with another closely related SNRI that increases synaptic serotonin and norepinephrine and is not approved in Europe but is widely prescribed in the US, is most likely taking which second drug?\n\nAnswer: desvenlafaxine", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 1056, "completion_tokens": 77, "total_tokens": 1133, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680141fbebb881908360f8af959467b7", "custom_id": "Lidocaine-Pamidronic acid-thiotepa-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "e08ca795e60353079056bdbcfbb2fae3", "body": {"id": "chatcmpl-BNNplwVUymhoBwDvDzT73nhklPQgp", "object": "chat.completion", "created": 1744912861, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient undergoing cancer therapy is being considered for medication to manage osteoporosis. During treatment, a nitrogen-containing bisphosphonate\u2014approved for medical use since the 1980s and used specifically for preventing osteoporosis\u2014is administered. It is observed that, when this bisphosphonate is given in conjunction with a certain organophosphorus anti-cancer agent (whose chemical formula is (C2H4N)3PS and which is marketed under brands such as Tepadina), there is an increased risk of erythema. Which anti-cancer medication, when co-administered with the bisphosphonate described, is associated with this risk?\n\nAnswer: thiotepa", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 715, "completion_tokens": 139, "total_tokens": 854, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680141fc0054819086fd4e18dbddf88f", "custom_id": "Citalopram-oxybutynin-Pirbuterol-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "bffc4cbb5a366b604881c7bc5670cdda", "body": {"id": "chatcmpl-BNNpnvl1d9iC0dayu2qlpYG76RdHY", "object": "chat.completion", "created": 1744912863, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient with overactive bladder managed by an antimuscarinic agent that may cause xerostomia and thermoregulatory dysfunction is considering an inhaled \u03b22 adrenoreceptor agonist indicated for asthma relief. Based on drug-drug interaction data indicating a risk of apoplexy when these two medications are combined, which medication should be avoided as the asthma treatment option in this context?\n\nAnswer: Pirbuterol", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 891, "completion_tokens": 86, "total_tokens": 977, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_cf18407276"}}, "error": null}
{"id": "batch_req_680141fc13148190922692735477a6f1", "custom_id": "Naproxen-Lamotrigine-Amiloride-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "5d65726a1f9b3290ef714f2e4935d25a", "body": {"id": "chatcmpl-BNNpoD8Tmrv7du2459UlTMnTAa7fH", "object": "chat.completion", "created": 1744912864, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient with epilepsy who is stabilized on a medication that inhibits voltage-sensitive sodium channels to reduce excitatory neurotransmitter release begins to experience unwanted weight gain. Their clinician attributes this effect to the introduction of a medication that inhibits epithelial sodium channels in the distal nephron to conserve potassium while managing hypertension. Which potassium-conserving diuretic was most likely added to their regimen?\n\nAnswer: Amiloride", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 932, "completion_tokens": 82, "total_tokens": 1014, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680141fc26bc8190acab842be902b683", "custom_id": "Diazepam-Ibuprofen-desvenlafaxine-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "75de755bb5c5368bd19f2696e755b4bb", "body": {"id": "chatcmpl-BNNpqmblEVHPa1eOVCKP3KapUaXKb", "object": "chat.completion", "created": 1744912866, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient is prescribed an oral medication that acts as a serotonin and norepinephrine reuptake inhibitor for major depressive disorder, which can cause adverse events such as dizziness, hypertension, and risk of serotonin syndrome. If this patient takes a common NSAID used for headache and arthritis relief, known for causing gastrointestinal irritation and renal risk, what medication could their NSAID interact with to increase the risk of vaginal bleeding?\n\nAnswer: desvenlafaxine", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 1071, "completion_tokens": 92, "total_tokens": 1163, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fc39488190a94403617d270a99", "custom_id": "Ketoprofen-oxybutynin-Pirbuterol-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "5855015e844f2f6b77e95b55a7aad696", "body": {"id": "chatcmpl-BNNprdUNoeSi5zU6cxddlTBvLffRv", "object": "chat.completion", "created": 1744912867, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nAmong the following options: a nonsteroidal anti-inflammatory drug from the propionic acid class first used in 1980, an anticholinergic agent indicated for overactive bladder with a history of off-label use for hyperhidrosis, and a short-acting \u03b22 adrenoreceptor agonist inhaler used for asthma since 1983, which drug, when co-administered with the antimuscarinic agent for urinary disorders, is associated with an increased risk of apoplexy according to documented drug-drug interactions?\n\nAnswer: Pirbuterol", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 684, "completion_tokens": 116, "total_tokens": 800, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fc4d1c819088ce684acca5f9d3", "custom_id": "Bumetanide-vincristine-Torasemide-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "f0fa6b0a0459c7873c196dc0d532ec0d", "body": {"id": "chatcmpl-BNNptxthR5JrmlcYmk2sasDt67nfN", "object": "chat.completion", "created": 1744912869, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA loop diuretic utilized primarily for edema in cardiac, hepatic, or nephrological conditions, due to its inhibition of sodium-potassium-chloride cotransporter, can increase the risk of pneumonia when coadministered with a vinca alkaloid chemotherapeutic that impairs microtubule assembly, induces neuropathic side effects, and is strictly administered intravenously to avoid fatal complications. This chemotherapeutic agent, when combined with another sulfonamide loop diuretic\u2014often prescribed orally or intravenously for fluid overload from heart, kidney, or liver disease and known for adverse effects like hearing loss and hypokalemia\u2014can result in unspecified drug toxicity. Which medication, used for fluid overload and available as a generic based on a 1974 patent, is implicated in this toxicity interaction?\n\nAnswer: Torasemide", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 949, "completion_tokens": 172, "total_tokens": 1121, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fc5f8881908dc6890f57976e7d", "custom_id": "acetazolamide-Famotidine-Lamivudine-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "d23e98b438e30e098004a5d113ba2552", "body": {"id": "chatcmpl-BNNpwrFtJyZd5dRig2VpzCOOmxSSR", "object": "chat.completion", "created": 1744912872, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nWhich medication, known as a nucleoside reverse transcriptase inhibitor essential in the management of HIV and hepatitis B, has been reported to cause adenopathy when administered in combination with a histamine H2 receptor antagonist used for peptic ulcer disease and GERD, that may itself cause side effects such as headache and dizziness?\n\nAnswer: Lamivudine", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 927, "completion_tokens": 73, "total_tokens": 1000, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_cf18407276"}}, "error": null}
{"id": "batch_req_680141fc775c8190929a5020d2c04df7", "custom_id": "Amlodipine-Pamidronic acid-thiotepa-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "843bbd7ab44dbe748b2f30a6c9de1b9f", "body": {"id": "chatcmpl-BNNpxKMkuvYKvXEN1KlHl4Z7vmA0N", "object": "chat.completion", "created": 1744912873, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient with hypertension managed by a long-acting calcium channel antagonist develops erythema when this agent is co-administered with a nitrogen-containing bisphosphonate used to prevent osteoporosis. If the bisphosphonate is then administered with an organophosphorus anti-cancer medication, the same erythematous reaction is observed. Which agent is the anti-cancer medication involved in the second interaction?\n\nAnswer: thiotepa", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 579, "completion_tokens": 90, "total_tokens": 669, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680141fc893c8190839e0164704443e4", "custom_id": "indometacin-oxybutynin-Zaleplon-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "9df1397db54b9cb7cca96f892aa7f500", "body": {"id": "chatcmpl-BNNpXEi48CQI5RO6G4KxHKCk3Ov8v", "object": "chat.completion", "created": 1744912847, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nBased on reported drug-drug interactions, which medication used for insomnia, belonging to the pyrazolopyrimidine class and acting as a nonbenzodiazepine sedative-hypnotic, may induce apoplexy when taken in combination with an anticholinergic agent prescribed for overactive bladder?\n\nAnswer: Zaleplon", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 772, "completion_tokens": 71, "total_tokens": 843, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fc9bac8190b24bb628ec16a03f", "custom_id": "Candesartan-Desloratadine-Darunavir-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "a9de026e7fd8c4f56d1991d5dabafd6a", "body": {"id": "chatcmpl-BNNpZfYs1VBvy48CZj5Luhq1OtOVT", "object": "chat.completion", "created": 1744912849, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nWhich drug, known as a protease inhibitor used primarily for HIV/AIDS treatment and often combined with pharmacokinetic enhancers, is associated with acute pancreatitis when co-administered with an allergy medication that is a tricyclic H1 inverse agonist?\n\nAnswer: Darunavir", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 684, "completion_tokens": 60, "total_tokens": 744, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fcade88190817e6e5c6cb04631", "custom_id": "alendronic acid-Ibuprofen-Propofol-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "72bf956d21195f82b229ec81878c63eb", "body": {"id": "chatcmpl-BNNpYquDQlG4YstlDcK4vo4WEz8fe", "object": "chat.completion", "created": 1744912848, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nAmong the following agents\u2014one used orally to treat osteoporosis by inhibiting bone-resorbing cells, another widely utilized to reduce inflammation through suppression of pro-inflammatory prostaglandins, and a third administered as an intravenous, lipid-based formulation for rapid induction of general anesthesia via GABA_A receptor agonism\u2014which drug, when co-administered with the anti-inflammatory agent, is associated with the development of dysarthria (difficulty in articulating speech) according to documented interaction effects?\n\nAnswer: Propofol", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 941, "completion_tokens": 104, "total_tokens": 1045, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fcc12c81908106fc35fc852e47", "custom_id": "Methylphenidate-Megestrol-Desloratadine-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "a9e25c9f1ee0a85a1c5f1665e23e02dd", "body": {"id": "chatcmpl-BNNpaPJRER3A8NldjKCo40mXmjIGI", "object": "chat.completion", "created": 1744912850, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA tricyclic H1 inverse agonist used primarily in the treatment of allergies, which also serves as an active metabolite of another well-known antihistamine, is associated with a drug-drug interaction that can lead to weight loss when taken with a progestin from the 17\u03b1-hydroxyprogesterone group that has been used in treating endometrial and breast cancer as well as disease-related weight loss. Which drug, fitting this description, is the one involved in this weight loss interaction with the specified progestin?\n\nAnswer: Desloratadine", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 726, "completion_tokens": 118, "total_tokens": 844, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fcd3c4819080eca14235b7d962", "custom_id": "Alprazolam-Benazepril-Terazosin-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "9a8c9ec59b300d4f73b9f85f3066fa5b", "body": {"id": "chatcmpl-BNNpbKnEWBvbtlMMgSZD9YcoC0re5", "object": "chat.completion", "created": 1744912851, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient who is prescribed an oral ACE inhibitor commonly used for hypertension and diabetic nephropathy management, which may cause cough, asthenia, and potential angioedema, begins experiencing an increased risk of apoplexy after initiating treatment with a medication that relaxes blood vessels and the bladder to treat both enlarged prostate symptoms and high blood pressure (but is less preferred for hypertension). Which medication is the second drug that, when taken with the ACE inhibitor, can lead to this interaction?\n\nAnswer: Terazosin", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 872, "completion_tokens": 106, "total_tokens": 978, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fce6b48190bc274a3a6093f463", "custom_id": "Triazolam-Rosiglitazone-Bimatoprost-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "6391bfdc9abb9f8fdf9229b0dd02928f", "body": {"id": "chatcmpl-BNNpdgmCLTlVUZ1Dv8hqcHT2QHFEU", "object": "chat.completion", "created": 1744912853, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient with Type 2 diabetes managed by a thiazolidinedione that acts as a PPAR\u03b3 agonist, when this agent is combined with a medication commonly administered as an ophthalmic solution to increase eyelash growth and reduce intraocular pressure in cases of open angle glaucoma, is at risk of developing adenopathy as an interaction-related side effect. Which medication, described above, when co-administered with the diabetes agent, is associated with this risk?\n\nAnswer: Bimatoprost", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 860, "completion_tokens": 102, "total_tokens": 962, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fcf90c8190bde93ad06b2e49f1", "custom_id": "Rofecoxib-Telmisartan-Cinacalcet-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "b3505e39cd6121b76a5e35942cc15ad2", "body": {"id": "chatcmpl-BNNpfjVUfuzzybGLpVoBbLBc9OeGw", "object": "chat.completion", "created": 1744912855, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA COX-2-selective NSAID, once indicated for arthritic pain management but withdrawn from the market in 2004 due to increased risk of thrombosis and cardiovascular events, may cause cholecystitis when combined with an oral antihypertensive that antagonizes angiotensin II AT1 receptors and is noted for its use in heart failure but carries risks of renal impairment and potential for angioedema. When this antihypertensive is co-administered with a calcimimetic agent, first approved in 2004 for various forms of hyperparathyroidism and known to act by allosterically activating the calcium-sensing receptor, dysarthria can result. Which drug is the calcimimetic in this context?\n\nAnswer: Cinacalcet", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 876, "completion_tokens": 161, "total_tokens": 1037, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fd0bc48190ae75b551616984c4", "custom_id": "Diazepam-Gemfibrozil-Sildenafil-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "9e2a55982ed6fe748bf3945eb979bacc", "body": {"id": "chatcmpl-BNNphNMGUoyepTcIBP1WRalYUqTkQ", "object": "chat.completion", "created": 1744912857, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient is prescribed a fibrate medication to manage abnormal blood lipid levels, which may cause side effects such as muscle breakdown or gallstones. If this patient begins treatment with another drug\u2014a selective PDE5 inhibitor used for erectile dysfunction and pulmonary arterial hypertension\u2014what medication should the clinician be vigilant about, given the risk of erythema when these two drugs are co-administered?\n\nAnswer: Sildenafil", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 1037, "completion_tokens": 82, "total_tokens": 1119, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fd1e90819089952cdb2dad15e8", "custom_id": "Cetirizine-Sildenafil-Zaleplon-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "56d4b4ebf9eba110b7b70e16bb070ba1", "body": {"id": "chatcmpl-BNNpaqJKMBMGe2TfF3DVv8q3exY2f", "object": "chat.completion", "created": 1744912850, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nWhich medication, classified as a nonbenzodiazepine hypnotic of the pyrazolopyrimidine class used for insomnia, may be involved in an interaction with a phosphodiesterase type 5 inhibitor\u2014primarily indicated for erectile dysfunction and pulmonary arterial hypertension\u2014resulting in apoplexy according to their documented drug-drug interaction?\n\nAnswer: Zaleplon", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 856, "completion_tokens": 78, "total_tokens": 934, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fd31508190a468ab799519e72d", "custom_id": "Doxazosin-Metoprolol-Bimatoprost-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "88ac88509165b859fe6d2f69bd2239ea", "body": {"id": "chatcmpl-BNNpbAyJgrMJiGyrX4w5zf48GGGeJ", "object": "chat.completion", "created": 1744912851, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient being treated for angina pectoris and migraine prophylaxis with a cardioselective \u03b21-adrenergic receptor antagonist, who then begins therapy with an ophthalmic prostaglandin analog used to manage open angle glaucoma by increasing aqueous fluid outflow, may develop exertional shortness of breath as a drug-drug interaction. Based on these descriptions and relationships, which medication is most likely responsible for this interaction as described?\n\nAnswer: Bimatoprost", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 881, "completion_tokens": 97, "total_tokens": 978, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fd47d08190bcdb4756a9afd324", "custom_id": "Cimetidine-Labetalol-Metoprolol-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "3aa6d27f1ef4ecc948a492c59b0fefb4", "body": {"id": "chatcmpl-BNNpd9a7LiYvE6fqGZvHzAujgOCzX", "object": "chat.completion", "created": 1744912853, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient who is being treated for high blood pressure and angina with a medication that blocks both \u03b2- and \u03b1-adrenergic receptors and is available as a generic prescription develops apoplexy after starting a cardiospecific \u03b21-adrenergic receptor antagonist known for individualized dosing due to CYP2D6 variability. Which medication most likely precipitated the apoplexy in this context?\n\nAnswer: Metoprolol", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 848, "completion_tokens": 88, "total_tokens": 936, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fd59a88190880f597bdc93e936", "custom_id": "Labetalol-Metoprolol-Pirbuterol-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "4e5c0937a7c6f0b23a89bf38c27ac0fd", "body": {"id": "chatcmpl-BNNpfTN9TWSuSEaVKXvLVkkAXXuVL", "object": "chat.completion", "created": 1744912855, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA cardioselective \u03b21-adrenergic receptor antagonist widely used for cardiovascular conditions can cause erythema when combined with a short-acting \u03b22 adrenoreceptor agonist indicated for asthma that is delivered as a breath-activated metered-dose inhaler. Which medication, described above, is this asthma treatment?\n\nAnswer: Pirbuterol", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 772, "completion_tokens": 72, "total_tokens": 844, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fd6ba081908b4a782c4304ac0e", "custom_id": "Citalopram-Zolpidem-vincristine-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "edaeec0a27cfed9a444db121db855b9b", "body": {"id": "chatcmpl-BNNpgeZZqpDX2YMQ6mqEP5cpa1eI1", "object": "chat.completion", "created": 1744912856, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA selective serotonin reuptake inhibitor known for treating major depressive and anxiety disorders and notable for its risk of QT prolongation and serotonergic toxicity, when co-administered with a nonbenzodiazepine hypnotic indicated for short-term insomnia management and acting as a GABAA receptor positive modulator, has been associated with adenopathy. If this hypnotic agent is instead combined with a mitotic inhibitor, administered only intravenously and effective against leukemias and lymphoma by disrupting microtubule assembly, which drug is implicated in causing adenopathy in this latter combination?\n\nAnswer: vincristine", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 1081, "completion_tokens": 123, "total_tokens": 1204, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680141fd7e808190827dc3cb39892c79", "custom_id": "Lamotrigine-Dexpramipexole-Trimethoprim-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "1733092e8a4131012cbe9d1071a1d237", "body": {"id": "chatcmpl-BNNpiseiq1RKYjJmFWX8NOlbzYRGG", "object": "chat.completion", "created": 1744912858, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient is prescribed an oral investigational medicine that lowers blood and tissue eosinophils for eosinophilic asthma. When this medicine is taken with a certain antibiotic commonly used for bladder infections and also for Pneumocystis pneumonia, there is a reported risk of weight gain as an interaction. Based on this, which antibiotic is involved in this interaction?\n\nAnswer: Trimethoprim", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 826, "completion_tokens": 82, "total_tokens": 908, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fd8fe48190a47e565aeb5a8841", "custom_id": "Lamotrigine-Metolazone-Dexpramipexole-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "cb608d7aba192a621846bbb9d0a0f53b", "body": {"id": "chatcmpl-BNNpj5RQcvRjgjKAI0UMvITZaQnrF", "object": "chat.completion", "created": 1744912859, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient taking a thiazide-like diuretic prescribed for heart failure and hypertension, which lowers blood pressure by decreasing kidney reabsorption of water, experiences a loss of weight when co-administered with an investigational oral agent shown to significantly reduce blood eosinophil counts for eosinophilic asthma. Which drug is the investigational medicine that, in combination with the diuretic, results in this interaction?\n\nAnswer: Dexpramipexole", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 782, "completion_tokens": 97, "total_tokens": 879, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fda2d8819088603ac68bf67a47", "custom_id": "Naproxen-Zolpidem-Perindopril-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "d97f7d55628393187d62b29390ecedc0", "body": {"id": "chatcmpl-BNNpkLIlIBT9vJ8pZVTSL7D2q2VuL", "object": "chat.completion", "created": 1744912860, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient with insomnia, managed by a medication that acts as a positive allosteric modulator of the GABAA receptor and is known for its rapid sleep-onset effects and potential for neuropsychiatric disturbances, is also being treated with an antihypertensive agent that exerts its therapeutic benefits by inhibiting angiotensin II synthesis, thereby promoting vasodilation and natriuresis. According to documented drug interactions, which medication used for hypertension may be associated with weight loss when combined with this sleep aid?\n\nAnswer: Perindopril", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 1066, "completion_tokens": 114, "total_tokens": 1180, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fdb4b88190b877c820f8b29840", "custom_id": "Ketorolac-Duloxetine-Sorafenib-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "5db73016cdf0f5c7eaa6e93d8558f6e5", "body": {"id": "chatcmpl-BNNpmCc8JfaDsPoLytjtneLM4WnL5", "object": "chat.completion", "created": 1744912862, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA serotonin\u2013norepinephrine reuptake inhibitor used widely for depression and chronic pain syndromes has a known interaction with a kinase inhibitor therapy indicated for advanced cancers such as renal cell carcinoma and hepatocellular carcinoma, resulting in an increased risk of apoplexy when administered together. Which drug is the cancer therapy involved in this interaction?\n\nAnswer: Sorafenib", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 891, "completion_tokens": 76, "total_tokens": 967, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fdc5cc8190addf9a39a107cd20", "custom_id": "Zafirlukast-Duloxetine-Sorafenib-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "26ed54a8aa92c3a68a7d9797357f86e2", "body": {"id": "chatcmpl-BNNpozb77TIZ2q4x82ZB8pXEYAVEC", "object": "chat.completion", "created": 1744912864, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient receiving an orally bioavailable leukotriene receptor antagonist that targets airway inflammation and a serotonin\u2013norepinephrine reuptake inhibitor used for mood and pain disorders begins to experience apoplexy after starting a third medication. Which medication, indicated for advanced renal cell and hepatocellular carcinomas as well as thyroid carcinoma, is most likely the culprit?\n\nAnswer: Sorafenib", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 792, "completion_tokens": 80, "total_tokens": 872, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680141fdd8d4819086c82c90e9d485d7", "custom_id": "chlortalidone-Sildenafil-Zaleplon-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "0852c7b3929a0b30201cabaa0762e7f7", "body": {"id": "chatcmpl-BNNppYgEtYhDAgnk5Qw12az4n9iHu", "object": "chat.completion", "created": 1744912865, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA medication used primarily to treat erectile dysfunction and pulmonary arterial hypertension, which acts by selectively inhibiting phosphodiesterase type 5 to enhance nitric oxide-mediated vasodilation, can interact with a sedative-hypnotic from the pyrazolopyrimidine class indicated for insomnia, resulting in an increased risk of apoplexy. Based on this interaction, which drug, described above, is the sedative-hypnotic involved in this adverse effect?\n\nAnswer: Zaleplon", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 878, "completion_tokens": 102, "total_tokens": 980, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_cf18407276"}}, "error": null}
{"id": "batch_req_680141fdeab08190bb2d76bd3c2ced5e", "custom_id": "Naproxen-Minoxidil-Perindopril-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "71d63625d0ea843ae9213ef3badd268a", "body": {"id": "chatcmpl-BNNprf4s56APALfMHs0soOHRzqX37", "object": "chat.completion", "created": 1744912867, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient receiving an oral vasodilator used for hypertension and pattern hair loss develops thrombocytopenia when treated concomitantly with an ACE inhibitor that is a prodrug metabolized to an active moiety suppressing aldosterone biosynthesis and used for stable coronary artery disease. Which agent is the ACE inhibitor involved in this drug-drug interaction?\n\nAnswer: Perindopril", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 831, "completion_tokens": 78, "total_tokens": 909, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680141fdfcf88190847730d6d676a079", "custom_id": "Naproxen-Carvedilol-Metolazone-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "4c6f8e967294b644f4aab3896486e4e1", "body": {"id": "chatcmpl-BNNpstmIAK6USPjdZOFaiXcMiTfxI", "object": "chat.completion", "created": 1744912868, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA nonselective beta-adrenergic blocker with alpha-1 antagonism, commonly prescribed for hypertension and heart failure, may interact with a thiazide-like diuretic used for managing fluid overload in heart failure and hypertension, resulting in the adverse effect of erythema. Which drug is this diuretic?\n\nAnswer: Metolazone", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 921, "completion_tokens": 74, "total_tokens": 995, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fe11748190b04e9ee1ee62f1a5", "custom_id": "Aciclovir-Citalopram-Ranolazine-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "99b20d27375e390b6c6ba30ce81df52f", "body": {"id": "chatcmpl-BNNpuGRZ6zY4JMAFnU0XG8R9MXLmB", "object": "chat.completion", "created": 1744912870, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA chiral bicyclic phthalane derivative that acts as an SSRI and undergoes hepatic metabolism via the CYP2C19, CYP3A4, and CYP2D6 enzymes is known to interact with a medication used to treat heart-related chest pain, with this combination sometimes resulting in bursitis. Which drug for heart-related chest pain is implicated in this interaction?\n\nAnswer: Ranolazine", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 893, "completion_tokens": 83, "total_tokens": 976, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680141fe25108190ab49ec52f81a5e74", "custom_id": "Famotidine-Lamivudine-Metoprolol-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "7a0a99349030b86290948c5c8e81fd61", "body": {"id": "chatcmpl-BNNq1MjYeG4WrEr1iclsRd9k940AY", "object": "chat.completion", "created": 1744912877, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient being treated for chronic hepatitis B virus with a nucleoside reverse transcriptase inhibitor\u2014known for its safety in pregnancy and risk of hepatotoxicity\u2014begins experiencing dysarthria after the addition of a cardioselective \u03b21-adrenergic receptor antagonist commonly prescribed for angina and hypertension. Which medication, known for variable metabolism by CYP2D6 and negative inotropic effects, is most likely responsible for this adverse interaction?\n\nAnswer: Metoprolol", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 907, "completion_tokens": 98, "total_tokens": 1005, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680141fe39b8819090b493c2fbd1b2ba", "custom_id": "Naproxen-Furosemide-Oxaprozin-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "a9625d7d5f1796c5b9821a2a1035483c", "body": {"id": "chatcmpl-BNNpaFFCaZoQtnWkZPm8BayUxbtC1", "object": "chat.completion", "created": 1744912850, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA potent loop diuretic, known for its use in treating edema and hypertension but associated with risks such as hypokalemia and ototoxicity, is documented to produce gastric inflammation when combined with a nonsteroidal anti-inflammatory drug that is a propionic acid derivative used for arthritis in both adults and children over 6 years. Based on this drug-drug interaction causing gastric inflammation, which drug is involved?\n\nAnswer: Oxaprozin", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 917, "completion_tokens": 91, "total_tokens": 1008, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fe4eb081908354a6a8b047547f", "custom_id": "Methylphenidate-Ziprasidone-Desloratadine-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "feabaac597557cc2e32ecc5fd46a34f2", "body": {"id": "chatcmpl-BNNpcxpYIXHvUf3tfhyXo9rMEY3Fu", "object": "chat.completion", "created": 1744912852, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient with schizophrenia controlled by a medication that modulates serotonergic and dopaminergic neurotransmission and is known for less propensity for weight gain than most similar antipsychotics is prescribed a new treatment for allergies, which is a tricyclic H1 inverse agonist and the active metabolite of loratadine. What is the allergy medication that, when combined with the antipsychotic, can result in an increased heart rate?\n\nAnswer: Desloratadine", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 872, "completion_tokens": 97, "total_tokens": 969, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fe64c48190affab648e937f5dd", "custom_id": "Duloxetine-Desloratadine-Darunavir-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "0946a59133ef35806a11b53b0bd6892a", "body": {"id": "chatcmpl-BNNpdwH2Af1XbvQ9SoqJbnQvQduDB", "object": "chat.completion", "created": 1744912853, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient being treated for allergies with a tricyclic H1 inverse agonist that is the active metabolite of loratadine develops acute pancreatitis after the addition of an antiretroviral protease inhibitor, which is commonly used in combination with pharmacokinetic boosters for HIV/AIDS therapy. Which medication is most likely responsible for this interaction with the allergy agent?\n\nAnswer: Darunavir", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 828, "completion_tokens": 81, "total_tokens": 909, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fe790c8190978adc3f8c3b8fa2", "custom_id": "Tramadol-Telmisartan-solifenacin-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "34bb6a6f9d60eeafd53fd92a752df194", "body": {"id": "chatcmpl-BNNpfnzWGVrhLbwHOzRVNbjMUD8qX", "object": "chat.completion", "created": 1744912855, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient taking an angiotensin II receptor antagonist to manage hypertension experiences dysarthria after initiating therapy for overactive bladder symptoms characterized by urinary urgency and incontinence. Based on reported drug-drug interactions and the mechanisms of action of these medications, which oral antimuscarinic agent is most likely implicated in this interaction?\n\nAnswer: solifenacin", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 876, "completion_tokens": 72, "total_tokens": 948, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fe8e588190bf19314c5c9caac5", "custom_id": "Celecoxib-Oxaprozin-Sildenafil-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "2d3b95315496b3ce430e4c90b4af316e", "body": {"id": "chatcmpl-BNNpgECc8iT7XmMj1NvQcYFQZMe1K", "object": "chat.completion", "created": 1744912856, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient receiving therapy with a selective phosphodiesterase type 5 inhibitor, characterized by its primary use in enhancing blood flow for erectile dysfunction and pulmonary arterial hypertension, develops gastric inflammation when this medication is combined with a propionic acid derivative NSAID used for joint pain and stiffness. Which drug is most likely being coadministered with the propionic acid derivative to result in this adverse gastrointestinal interaction?\n\nAnswer: Sildenafil", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 919, "completion_tokens": 86, "total_tokens": 1005, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fea280819099a9db2b43610894", "custom_id": "Naproxen-Lamotrigine-Zolpidem-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "eab97a8a3eeca30b72d9f86ca624b514", "body": {"id": "chatcmpl-BNNpfzFblHvaq3hZ3q8yVuNdn0CV5", "object": "chat.completion", "created": 1744912855, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient with epilepsy managed by a medication that inhibits excitatory neurotransmitter release through sodium and calcium channel modulation wishes to address new-onset insomnia. Which short-acting hypnotic, known to decrease sleep latency by enhancing GABAA receptor-mediated inhibition, should be avoided due to its potential to induce interstitial cystitis when combined with the anticonvulsant?\n\nAnswer: Zolpidem", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 1062, "completion_tokens": 81, "total_tokens": 1143, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141feb6cc81909f337007e32284a6", "custom_id": "Doxazosin-Metoprolol-Pirbuterol-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "2f26a706e032dc7740cbefbacfda6ab1", "body": {"id": "chatcmpl-BNNpgCzGOQjPA5YNLpCNNSDyv9Tzo", "object": "chat.completion", "created": 1744912856, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient currently managed for angina and migraine prophylaxis with a cardioselective \u03b21-adrenergic receptor antagonist develops erythema after starting a new bronchodilating, short-acting \u03b22 agonist delivered via a breath-activated inhaler for asthma treatment. Which added medication is most likely responsible for this interaction?\n\nAnswer: Pirbuterol", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 763, "completion_tokens": 74, "total_tokens": 837, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fec9a08190b28a04e4034d48d2", "custom_id": "Rofecoxib-Zolpidem-Bimatoprost-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "c3c4c317f9faa564efda99a582830acb", "body": {"id": "chatcmpl-BNNphW1T9T12tXrD4b0aCvQ3oBQyO", "object": "chat.completion", "created": 1744912857, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient being treated for short-term insomnia with a nonbenzodiazepine hypnotic agent that enhances GABAergic inhibition is prescribed an additional medication to manage open-angle glaucoma by increasing aqueous humor outflow via prostaglandin analog action. According to reported drug-drug interactions, which of the following could occur as a result of co-administering these two agents: abnormal ECG findings, adenopathy, or increased cardiovascular events? Identify the drug used for glaucoma that is implicated in this abnormal ECG interaction.\n\nAnswer: Bimatoprost", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 1000, "completion_tokens": 110, "total_tokens": 1110, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141fedbf881909b23ec437957fc10", "custom_id": "nevirapine-Ofloxacin-Imatinib-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "005d4a627bd59f4e91ff7f919aefba2a", "body": {"id": "chatcmpl-BNNpj6oixGUZFRqW16cJJFkCxCTR6", "object": "chat.completion", "created": 1744912859, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient being treated for bacterial infections with a DNA synthesis inhibitor that targets DNA gyrase and topoisomerase IV\u2014commonly prescribed for pneumonia, urinary tract infections, and ophthalmic conditions\u2014begins to experience weight gain only after initiating an ATP-competitive tyrosine kinase inhibitor primarily used for Philadelphia chromosome-positive leukemias and gastrointestinal stromal tumors. Based on known drug-drug interactions, which drug is most likely to be responsible for the onset of this side effect when combined with the antibiotic?\n\nAnswer: Imatinib", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 951, "completion_tokens": 109, "total_tokens": 1060, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680141feeda081908b54a3f0191faabc", "custom_id": "Lidocaine-Metoprolol-Fulvestrant-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "3cb9ef5ea86cfeae7e6989a667b5c1df", "body": {"id": "chatcmpl-BNNpkGYxtYVa4xpbah9DFDxPRAHvO", "object": "chat.completion", "created": 1744912860, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient undergoing therapy with a cardioselective \u03b21-adrenergic receptor antagonist known for managing hypertension and migraines reports the onset of upper abdominal pain after starting a new injectable medication used to treat hormone receptor-positive metastatic breast cancer in postmenopausal women. Which medication most likely contributed to the development of this upper abdominal pain when combined with the described cardiovascular agent?\n\nAnswer: Fulvestrant", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 959, "completion_tokens": 82, "total_tokens": 1041, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680141fefef88190854bc9af5a7e4d82", "custom_id": "Carvedilol-Dexpramipexole-Ticlopidine-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "dc75d829aa9b196a2df0b088da70072a", "body": {"id": "chatcmpl-BNNpmcPp4NIP4k83lJQmjuFGjhZLC", "object": "chat.completion", "created": 1744912862, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nWhich medication, known for reducing the risk of thrombotic strokes by inhibiting ADP receptors, has been associated with hyperglycaemia when taken together with a first-in-class investigational oral treatment designed to lower blood and tissue eosinophils in eosinophilic asthma?\n\nAnswer: Ticlopidine", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 808, "completion_tokens": 65, "total_tokens": 873, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680141ff153c81908e3799775d0b640e", "custom_id": "Efavirenz-Lamivudine-Metoprolol-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "b7313e2505d343764c5dd3fd0da4aa4b", "body": {"id": "chatcmpl-BNNpnZQ6NcUTTrk7iDfgrarWW2u23", "object": "chat.completion", "created": 1744912863, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nWhich medication, commonly used for cardiovascular conditions such as angina, hypertension, and arrhythmias, and whose pharmacokinetics are significantly impacted by CYP2D6 variability, is likely to cause dysarthria when co-administered with an antiretroviral nucleoside reverse transcriptase inhibitor used against HIV and hepatitis B?\n\nAnswer: Metoprolol", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 948, "completion_tokens": 77, "total_tokens": 1025, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680141ff29b48190a4bb381fd8a6a838", "custom_id": "Lamivudine-Metoprolol-Pirbuterol-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "5e7e23beaf91471d4c6234b7d2d2555b", "body": {"id": "chatcmpl-BNNpof5zY94QKGHKrkilRRm04AMl6", "object": "chat.completion", "created": 1744912864, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient treating chronic viral hepatitis with a nucleoside reverse transcriptase inhibitor (which can cause cephalalgia and hepatotoxicity but is generally safe in pregnancy) is also prescribed a cardioselective \u03b21-blocker for hypertension. When this \u03b21-blocker\u2014well known for its prudent use due to CYP2D6 metabolic variability\u2014is subsequently combined with a short-acting \u03b22 agonist dispensed as a breath-activated metered-dose inhaler for asthma, erythema is observed as a result of this combination. Based on the known interactions, which drug added to the \u03b21-blocker regimen precipitates this erythema?\n\nAnswer: Pirbuterol", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 803, "completion_tokens": 137, "total_tokens": 940, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141ff3be881909fa6a6ae6b0caf29", "custom_id": "Ketorolac-Duloxetine-Desloratadine-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "91f9f90defcada49e1bd4705361733c7", "body": {"id": "chatcmpl-BNNpqTEpENDTKZZsd193OxQARCjzP", "object": "chat.completion", "created": 1744912866, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA serotonin\u2013norepinephrine reuptake inhibitor known for its use in alleviating depressive and anxiety disorders is associated with causing gastric inflammation when combined with a tricyclic H1 inverse agonist used to treat allergies. Which drug is this antihistamine that, when used alongside the described SNRI, may increase the risk of gastric inflammation?\n\nAnswer: Desloratadine", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 917, "completion_tokens": 79, "total_tokens": 996, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_cf18407276"}}, "error": null}
{"id": "batch_req_680141ff4ed08190aa87432b2fd09ea1", "custom_id": "Norfloxacin-Zolpidem-solifenacin-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "ff391d1f92f7e45008a8c36da6cb4f4a", "body": {"id": "chatcmpl-BNNpr8EZkj2TG0HKD5HH1s29mWzxP", "object": "chat.completion", "created": 1744912867, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA medication primarily indicated for the short-term treatment of insomnia, working as a GABAA receptor modulator, may interact with a drug that decreases bladder contractions (used for overactive bladder and neurogenic detrusor overactivity) to cause weight loss. Which drug that helps with urinary frequency and urgency is involved in this interaction?\n\nAnswer: solifenacin", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 899, "completion_tokens": 74, "total_tokens": 973, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_cf18407276"}}, "error": null}
{"id": "batch_req_680141ff62f48190a7a6a461c0d4808e", "custom_id": "Metronidazole-vincristine-Torasemide-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "0bfab1dd4a4ba807be5744b8fd0b2899", "body": {"id": "chatcmpl-BNNpuzdLnoo3k4cARmTuvbGgjRj2V", "object": "chat.completion", "created": 1744912870, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient undergoing chemotherapy for acute lymphoblastic leukemia is treated with a vinca alkaloid that inhibits microtubule assembly, and who also receives a sulfonamide loop diuretic used primarily for fluid overload due to heart failure or kidney disease. Based on known drug-drug interactions, which medication in this scenario is associated with an increased risk of nonspecific drug toxicity when co-administered with this mitotic inhibitor?\n\nAnswer: Torasemide", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 946, "completion_tokens": 95, "total_tokens": 1041, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680141ff74608190a69e166642c0389d", "custom_id": "Furosemide-Zolpidem-Perindopril-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "1822a0693c7eeccc57bac780eda0f5f9", "body": {"id": "chatcmpl-BNNpvKQRTu7b02JgnOQ8edxLPph0e", "object": "chat.completion", "created": 1744912871, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA nonbenzodiazepine hypnotic agent known for reducing sleep latency, when taken together with a long-acting ACE inhibitor that promotes vasodilation and natriuresis for the treatment of hypertension and heart failure, can lead to which drug-associated outcome according to their documented interaction?\n\nAnswer: Perindopril", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 1064, "completion_tokens": 66, "total_tokens": 1130, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680141ff85d48190958e7f41c19b9cc1", "custom_id": "Furosemide-Zolpidem-solifenacin-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "1fd9ebea7b2bf9c896de688ed16778ae", "body": {"id": "chatcmpl-BNNpwjKDSBrg4lmx2EuZbU0rdnKG7", "object": "chat.completion", "created": 1744912872, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nAmong the following drugs\u2014a potent loop diuretic prescribed for fluid overload and hypertension, a nonbenzodiazepine hypnotic agent used for short-term insomnia management, and an oral antimuscarinic medication indicated for overactive bladder\u2014which one, when combined with the nonbenzodiazepine hypnotic, is associated with loss of weight as an interaction outcome?\n\nAnswer: solifenacin", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 1020, "completion_tokens": 80, "total_tokens": 1100, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680141ff988081908036c2c8e83dd53b", "custom_id": "Temazepam-Megestrol-Desloratadine-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "c2e59e7894e8c6646d68ef06fc850eb5", "body": {"id": "chatcmpl-BNNpyfT4yIFpSKR15xZB3s55gzEoB", "object": "chat.completion", "created": 1744912874, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nWhich drug, known as an active metabolite of another tricyclic antihistamine and introduced to the market in the early 2000s for allergy treatment, is associated with weight loss when taken together with a progestin used for cancer-related conditions and disease-related weight loss, but is not implicated in increasing the risk of cholecystitis when combined with a benzodiazepine hypnotic used for severe insomnia?\n\nAnswer: Desloratadine", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 733, "completion_tokens": 95, "total_tokens": 828, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_cf18407276"}}, "error": null}
{"id": "batch_req_680141ffac248190aad6fb40539c2092", "custom_id": "Risedronic acid-Zolpidem-Bimatoprost-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "44ff5c40759c07d04098e23328b9b2d6", "body": {"id": "chatcmpl-BNNpzXUiuLhV8eVSshqsicgriKKIM", "object": "chat.completion", "created": 1744912875, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient taking an oral nonbenzodiazepine hypnotic classified as an imidazopyridine for short-term insomnia management, who then begins using an eye drop prostaglandin analog for open angle glaucoma that is also marketed for eyelash growth, is at risk of experiencing abnormal ECG findings as a result of the interaction between these two medications. Which medication is the recently added agent used to treat elevated intraocular pressure and potentially affect eyelash length?\n\nAnswer: Bimatoprost", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 852, "completion_tokens": 101, "total_tokens": 953, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680141ffbdf88190bb2fb8dc97d50c9b", "custom_id": "Naproxen-Capecitabine-Desloratadine-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "d78bd92b70055c61d34eaa396f806c6a", "body": {"id": "chatcmpl-BNNq1aYwWePCmJqaZiqvR9zFVNAnh", "object": "chat.completion", "created": 1744912877, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient is being treated with an orally administered anticancer prodrug from the fluoropyrimidine class, which is converted in vivo to 5-fluorouracil, and is known for side effects such as abdominal pain, diarrhea, and cardiotoxicity. If this patient is also prescribed a tricyclic H1 inverse agonist used for allergy relief, which is an active metabolite of loratadine, what medication could increase the nonspecific drug toxicity associated with the anticancer agent?\n\nAnswer: Desloratadine", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 840, "completion_tokens": 110, "total_tokens": 950, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_cf18407276"}}, "error": null}
{"id": "batch_req_680141ffd2f4819083845a89b07e2299", "custom_id": "Etiracetam-Ziprasidone-Desloratadine-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "3333a5adf68aa5f384adf4b1c9399ea4", "body": {"id": "chatcmpl-BNNq3Y9kE6Iq3bl5lpizUd2joLnZq", "object": "chat.completion", "created": 1744912879, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA second-generation antipsychotic, available in oral and intramuscular forms for psychiatric conditions like schizophrenia and bipolar disorder, is reported to increase heart rate when combined with a tricyclic H1 inverse agonist that is an active metabolite of loratadine and used to treat allergies. Which drug is this antihistamine?\n\nAnswer: Desloratadine", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 686, "completion_tokens": 76, "total_tokens": 762, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680141ffe8d88190ae66a0c5c88a6e72", "custom_id": "Haloperidol-Rosiglitazone-Bimatoprost-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "8a1f5024f3f8935eb822b3e40d7e7fa0", "body": {"id": "chatcmpl-BNNq4sL3UFAvmecwgvAKyNDrhWBNi", "object": "chat.completion", "created": 1744912880, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA thiazolidinedione-class antidiabetic agent, once widely used for its ability to increase insulin sensitivity but now restricted due to cardiovascular concerns, can interact with a medication administered as an eye drop to manage open angle glaucoma and promote eyelash growth. This interaction has been associated with adenopathy. Which drug is the glaucoma medication?\n\nAnswer: Bimatoprost", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 927, "completion_tokens": 76, "total_tokens": 1003, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680141fffabc8190853e89cf3e3501bf", "custom_id": "Diazepam-Pyridostigmine-Telithromycin-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "ff51b52d0ae0368656980a2494e51bad", "body": {"id": "chatcmpl-BNNq5GkIjkRhb5uA9VRySzTrl8hbx", "object": "chat.completion", "created": 1744912881, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient being treated for myasthenia gravis with a quaternary ammonium acetylcholinesterase inhibitor develops dysarthria after being prescribed an antibiotic that is a semi-synthetic erythromycin derivative indicated for community-acquired pneumonia. Which antibiotic is most likely responsible for this interaction?\n\nAnswer: Telithromycin", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 1028, "completion_tokens": 67, "total_tokens": 1095, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680142000d3c8190a299a840f7ac72fe", "custom_id": "Tramadol-Ziprasidone-Desloratadine-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "ed87a586af7b96ab2b1c211ba4566ecf", "body": {"id": "chatcmpl-BNNq6kJ6HUsegzQCWUEUVJrkgijTf", "object": "chat.completion", "created": 1744912882, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient is currently prescribed a second-generation atypical antipsychotic that primarily operates through serotonergic and dopaminergic pathways and is frequently used to treat schizophrenia or bipolar disorder. If this patient co-administers a tricyclic H1 inverse agonist commonly prescribed for allergies\u2014which serves as the active metabolite of loratadine\u2014what medication could specifically increase their heart rate based on documented drug-drug interactions?\n\nAnswer: Desloratadine", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 853, "completion_tokens": 92, "total_tokens": 945, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_6801420027d481908babe69ddb25c38a", "custom_id": "Doxazosin-Metoprolol-Acitretin-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "b152c3936917ebc9f8f0dd3df01f1507", "body": {"id": "chatcmpl-BNNq8FwlDMYneS4esTKhYecjNxMdA", "object": "chat.completion", "created": 1744912884, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nWhich oral medication, prescribed primarily for severe, treatment-resistant psoriasis and known to induce keratinocyte differentiation, is associated with weight loss when co-administered with a cardioselective \u03b21-adrenergic antagonist used for angina, hypertension, and arrhythmias?\n\nAnswer: Acitretin", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 870, "completion_tokens": 64, "total_tokens": 934, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_cf18407276"}}, "error": null}
{"id": "batch_req_680142003b108190ae3c6ed981b6b565", "custom_id": "Alprazolam-Ciclopirox-hydroxychloroquine-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "3b6a79b28fd3cbf31c51fc2cd6058d3b", "body": {"id": "chatcmpl-BNNqAAXoM2p3b4wEDQAGjmGaADZjj", "object": "chat.completion", "created": 1744912886, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient with moderate onychomycosis being treated with a topical antifungal commonly prescribed for nail and scalp conditions develops adenopathy after starting another orally-administered medication indicated for malaria prophylaxis and autoimmune diseases like lupus erythematosus. Which drug most likely interacted with the antifungal to cause this adverse effect?\n\nAnswer: hydroxychloroquine", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 842, "completion_tokens": 74, "total_tokens": 916, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680142004c708190bcd09cba4d1fdd1a", "custom_id": "Candesartan-Pamidronic acid-thiotepa-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "29e4f7be3a91bbd367e1d68c4ee7b28d", "body": {"id": "chatcmpl-BNNqBWmyf1rghkBj5YyF6mnPyIukj", "object": "chat.completion", "created": 1744912887, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient being treated for osteoporosis with a nitrogen-containing bisphosphonate who begins therapy with an anti-cancer organophosphorus compound may experience an increased risk of erythema due to a drug-drug interaction. Which agent, described as an organophosphorus compound and anti-cancer medication, is involved in this interaction?\n\nAnswer: thiotepa", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 515, "completion_tokens": 75, "total_tokens": 590, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680142005dc4819090e7cb9a4ef4f72e", "custom_id": "folinic acid-Pamidronic acid-thiotepa-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "3ede2eccc518b4b329fb9bcee3c49aef", "body": {"id": "chatcmpl-BNNqCJuBQiJqkdXmNovDVvKrxjtTO", "object": "chat.completion", "created": 1744912888, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA nitrogen-containing bisphosphonate used to prevent osteoporosis may cause erythema when administered with which anti-cancer medication that is an organophosphorus compound?\n\nAnswer: thiotepa", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 605, "completion_tokens": 41, "total_tokens": 646, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_6801420076108190960dfa832a153557", "custom_id": "Naproxen-alendronic acid-Efavirenz-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "a3959482bf303dadbb23444b8bb8c511", "body": {"id": "chatcmpl-BNNqD0mPcPiFVDbOypyGiwdohu4qF", "object": "chat.completion", "created": 1744912889, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient undergoing treatment for osteoporosis and Paget's disease of bone with a bisphosphonate medication that should be taken with calcium is noted to experience adenopathy when this medication is taken with an antiretroviral agent that allosterically inhibits HIV-1 reverse transcriptase and is contraindicated in pregnancy due to teratogenicity. Which medication, commonly used in such antiretroviral regimens, is associated with this interaction?\n\nAnswer: Efavirenz", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 941, "completion_tokens": 96, "total_tokens": 1037, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_cf18407276"}}, "error": null}
{"id": "batch_req_6801420089248190b436b02829e4821d", "custom_id": "indometacin-vincristine-Torasemide-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "81f458c240a57178e5e2f6375de558bb", "body": {"id": "chatcmpl-BNNpflsCXub0gNiwFobGZPB0Cp7A8", "object": "chat.completion", "created": 1744912855, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient undergoing chemotherapy with a vinca alkaloid that disrupts microtubule assembly and is known for causing peripheral neuropathy and serious adverse effects is at increased risk of unspecified drug toxicity when treated for fluid overload stemming from heart or kidney disease with a sulfonamide loop diuretic that decreases sodium reabsorption and may cause increased urination and low blood potassium. Which medication, when co-administered with the mitotic inhibitor, results in this interaction?\n\nAnswer: Torasemide", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 863, "completion_tokens": 103, "total_tokens": 966, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680142009e38819086e1c9cb51a49177", "custom_id": "Amlodipine-Dexpramipexole-Ticlopidine-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "7c03b61d450d4abff0deda3d4cdce4fc", "body": {"id": "chatcmpl-BNNphc5HVz2tfDdJniihXkCJaaGJa", "object": "chat.completion", "created": 1744912857, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient with hypertension controlled by a long-acting calcium channel antagonist that works through vasodilation and a history of eosinophilic asthma being managed by an investigational oral agent that significantly lowers eosinophil counts develops hyperglycaemia after starting a new antiplatelet medication used in cases where aspirin is not tolerated and associated with rare blood disorders such as neutropenia. Which medication most likely contributed to the hyperglycaemia due to its interaction with the eosinophil-lowering agent?\n\nAnswer: Ticlopidine", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 752, "completion_tokens": 111, "total_tokens": 863, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_68014200b0c48190a770c26dbbd7f38a", "custom_id": "Candesartan-Lamivudine-Metoprolol-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "53ed4bec1649871d76c78a14c546d4f8", "body": {"id": "chatcmpl-BNNpipfAxymReTivLM05ePT8znh9C", "object": "chat.completion", "created": 1744912858, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient is being treated with a nucleoside reverse transcriptase inhibitor well-known for its use in combination antiretroviral therapy and is also prescribed a medication that exerts a cardioselective \u03b21-blocking effect and is commonly utilized in the management of hypertension, tachyarrhythmias, and migraine prophylaxis. According to knowledge of drug interactions, the concurrent use of these two medications may result in the development of dysarthria. Which drug is the cardioselective \u03b21-blocker in this interaction?\n\nAnswer: Metoprolol", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 833, "completion_tokens": 113, "total_tokens": 946, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_68014200c4f48190ad2eab4575fd73a2", "custom_id": "Fenofibrate-Modafinil-Bimatoprost-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "8641c5f9d940eb98d99702f942369d06", "body": {"id": "chatcmpl-BNNpfrVFHv2Xvecp7GoO2Z2Z0LQNo", "object": "chat.completion", "created": 1744912855, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient experiencing enhanced wakefulness secondary to a centrally acting eugeroic agent, commonly prescribed for narcolepsy and shift work sleep disorder, reports increased nighttime urination after initiating therapy for ocular hypertension with a prostaglandin analog primarily administered as an eye drop. Which drug is associated with this interaction with the wakefulness-promoting agent?\n\nAnswer: Bimatoprost", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 901, "completion_tokens": 78, "total_tokens": 979, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_68014200e3448190b4ce324f18a445ca", "custom_id": "Naproxen-Lamotrigine-Salmeterol-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "651a1872b1542dbd489c2ad0b54f18d2", "body": {"id": "chatcmpl-BNNpkBqcNBIbtTyp61x9QSvbYxjlf", "object": "chat.completion", "created": 1744912860, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA phenyltriazine anticonvulsant prescribed for epilepsy and bipolar disorder, when administered concomitantly with a long-acting \u03b22 adrenergic receptor agonist used to manage asthma and COPD symptoms via a dry-powder inhaler, may result in erythema. Which medication, characterized as a LABA for respiratory conditions, is implicated in this adverse dermatological interaction?\n\nAnswer: Salmeterol", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 943, "completion_tokens": 87, "total_tokens": 1030, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_68014200f684819082b5b08a3e1965a6", "custom_id": "Citalopram-Gemfibrozil-Sildenafil-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "9be83374170b0a4ebc254db015738b99", "body": {"id": "chatcmpl-BNNpmZowNidvBZA6UjnCeu8qFttLH", "object": "chat.completion", "created": 1744912862, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA hypolipidemic agent that may cause side effects such as headache and gallstones is known to induce metabolic encephalopathy when co-administered with a selective serotonin reuptake inhibitor used in treating major depressive disorder. When this same hypolipidemic agent is taken with a phosphodiesterase type 5 inhibitor used primarily for erectile dysfunction and pulmonary arterial hypertension, which drug is associated with increased risk of erythema due to this interaction?\n\nAnswer: Sildenafil", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 998, "completion_tokens": 99, "total_tokens": 1097, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680142010ac48190afd82979c12b6945", "custom_id": "Cimetidine-Pamidronic acid-thiotepa-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "ab4b778cf1b434b816cfd3adea44b5e9", "body": {"id": "chatcmpl-BNNpnzZvGFwlp3yG2ynvoZwcCR5Pe", "object": "chat.completion", "created": 1744912863, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA medication that is a nitrogen-containing bisphosphonate approved to prevent osteoporosis is known to cause erythema when combined with a histamine H2 receptor antagonist that inhibits stomach acid production. If this bisphosphonate is instead combined with an anti-cancer organophosphorus compound with the formula (C2H4N)3PS, which drug is also associated with an erythema interaction with the bisphosphonate?\n\nAnswer: thiotepa", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 565, "completion_tokens": 96, "total_tokens": 661, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680142011df88190ba10f757c6592c9e", "custom_id": "Fentanyl-Ketorolac-Oxaprozin-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "9d17ef4b1dd704ea0d1131995bb825fc", "body": {"id": "chatcmpl-BNNpgViQcuW1neXltbH5c7XBdngFl", "object": "chat.completion", "created": 1744912856, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA nonsteroidal anti-inflammatory drug that is a propionic acid derivative, prescribed for managing swelling and joint pain related to osteoarthritis and rheumatoid arthritis, may cause gastric inflammation when taken with another NSAID commonly used for short-term moderate to severe nociceptive pain management. Which drug matches this description?\n\nAnswer: Oxaprozin", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 957, "completion_tokens": 69, "total_tokens": 1026, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_6801420130548190999479e2c4c0ae78", "custom_id": "Alfuzosin-Benazepril-Terazosin-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "5246dd69615dd7fa929eb94086756f5a", "body": {"id": "chatcmpl-BNNphbcTTdaE5GSIGp2ZuLSwEPHFZ", "object": "chat.completion", "created": 1744912857, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient being treated for both hypertension and benign prostatic hyperplasia with an alpha-1 blocker developed decreased libido after the addition of an oral ACE inhibitor commonly used to manage blood pressure and diabetic nephropathy. Later, when this same ACE inhibitor was combined with another alpha-1 blocker\u2014also indicated for high blood pressure but considered a less preferred option\u2014the patient experienced apoplexy. Which medication, taken with the ACE inhibitor, is associated with the risk of apoplexy?\n\nAnswer: Terazosin", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 788, "completion_tokens": 104, "total_tokens": 892, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_68014201433c8190a37fe6be2fd879fa", "custom_id": "Candesartan-mitomycin C-vincristine-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "a66149f61cef4365313e3cd8c5bed9fb", "body": {"id": "chatcmpl-BNNpiq2VgThMvdWI9HsLBNyAPSCuO", "object": "chat.completion", "created": 1744912858, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA chemotherapeutic agent known for its antitumour activity can cause myelodysplasia when combined with an intravenously administered vinca alkaloid that disrupts microtubule assembly and is associated with toxicities such as peripheral neuropathy and myelosuppression. Based on these properties and interactions, which drug is the mitotic inhibitor in this drug combination?\n\nAnswer: vincristine", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 649, "completion_tokens": 82, "total_tokens": 731, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_6801420156b081909eeeb9b5bf71a6c7", "custom_id": "Cimetidine-Citalopram-oxybutynin-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "73a9edccd3b6463cb02acc4c7a86364e", "body": {"id": "chatcmpl-BNNpk8MewqNi62DPyVjN8BKr7zPFm", "object": "chat.completion", "created": 1744912860, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient being treated for major depressive disorder with an oral selective serotonin reuptake inhibitor that is metabolized by CYP2C19, CYP3A4, and CYP2D6 and may cause serotonergic toxicity starts experiencing cholecystitis upon introduction of an antimuscarinic agent used primarily to treat overactive bladder through the inhibition of acetylcholine-mediated smooth muscle contractions. Which drug is the antimuscarinic agent involved in this interaction?\n\nAnswer: oxybutynin", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 970, "completion_tokens": 101, "total_tokens": 1071, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680142016bc081909e604205de8fa9cc", "custom_id": "Famotidine-Sildenafil-Acamprosate-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "b6657ef313d77c3022820a7bc0c9bbba", "body": {"id": "chatcmpl-BNNpl6fH27AWa5hib5ruZCxK7JICb", "object": "chat.completion", "created": 1744912861, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient beginning treatment with a selective phosphodiesterase type 5 inhibitor for pulmonary arterial hypertension reports experiencing weight loss after starting a new medication intended to stabilize brain chemical signaling and reduce cravings during alcohol withdrawal. Which medication most likely contributed to this weight loss when combined with the PDE5 inhibitor?\n\nAnswer: Acamprosate", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 876, "completion_tokens": 67, "total_tokens": 943, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680142017e188190883446f305471309", "custom_id": "Alprazolam-Lidocaine-Pamidronic acid-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "f4be60756340747fa90eaae8a0834e6b", "body": {"id": "chatcmpl-BNNpntVWqqIwPnsirv8CGByfPqos7", "object": "chat.completion", "created": 1744912863, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nWhich drug, approved for medical use in 1987 and classified as a nitrogen-containing bisphosphonate for osteoporosis prevention, has been shown in combination with a local anesthetic that acts as a class Ib antiarrhythmic agent and sodium channel blocker to be associated with a risk of trigeminal neuralgia?\n\nAnswer: Pamidronic acid", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 869, "completion_tokens": 73, "total_tokens": 942, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_6801420191648190926f4a20cb354b94", "custom_id": "Furosemide-vincristine-Torasemide-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "c4183231cea31bec1be3e683f99f0839", "body": {"id": "chatcmpl-BNNpjvt9BazMqhxUmDyKpjhqtGTWj", "object": "chat.completion", "created": 1744912859, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient is undergoing chemotherapy with an intravenous agent that disrupts microtubule assembly to treat acute leukemias and Hodgkin's lymphoma, but is also known to cause peripheral neuropathy and severe toxicities. If this patient begins treatment with a sulfonamide loop diuretic used for fluid overload in heart, kidney, or liver disease and notable for side effects like increased urination, headache, and hypokalemia, which drug could increase the risk of drug toxicity when given with the chemotherapeutic agent?\n\nAnswer: Torasemide", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 965, "completion_tokens": 112, "total_tokens": 1077, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_68014201a7e48190a85a66008dae4cd5", "custom_id": "Metronidazole-Repaglinide-Perindopril-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "03781ec418fc16c0b151ad3e4c0586f7", "body": {"id": "chatcmpl-BNNpkqdRXNwnPKUowYEKKwHOe1jAB", "object": "chat.completion", "created": 1744912860, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient being treated for type 2 diabetes with a short-acting insulin secretagogue experiences nasal sinus congestion after beginning therapy with a long-acting ACE inhibitor that is contraindicated in pregnancy and requires hepatic activation. Which drug is most likely responsible for this interaction with the antidiabetic agent?\n\nAnswer: Perindopril", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 902, "completion_tokens": 67, "total_tokens": 969, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_cf18407276"}}, "error": null}
{"id": "batch_req_68014201bb188190b8238acd9896834e", "custom_id": "Furosemide-Lamotrigine-Fosphenytoin-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "c887ec372d9ea3c93269d99cf56a84b6", "body": {"id": "chatcmpl-BNNpmvlFyYUOFgTXCqZDCHBM2ZuB2", "object": "chat.completion", "created": 1744912862, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA widely prescribed anticonvulsant and mood stabilizer, known for treating various seizure types and bipolar disorder, can cause bradycardia when combined with an intravenous prodrug developed in the 1990s that is used for the acute treatment of convulsive status epilepticus. Which drug is this intravenous prodrug?\n\nAnswer: Fosphenytoin", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 855, "completion_tokens": 75, "total_tokens": 930, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_cf18407276"}}, "error": null}
{"id": "batch_req_68014201cf4881909e2e9b45af2b547e", "custom_id": "Doxazosin-Pamidronic acid-thiotepa-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "f9f24b886966174cc9a6dc1d9f44ab91", "body": {"id": "chatcmpl-BNNpoxyPzFqZ5aAvWngLtlThSibS2", "object": "chat.completion", "created": 1744912864, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA medication used to prevent osteoporosis may cause erythema when combined with an anti-cancer agent that is an organophosphorus compound with the formula (C2H4N)3PS. Based on these interactions, which drug is the anti-cancer agent that could lead to this side effect?\n\nAnswer: thiotepa", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 608, "completion_tokens": 69, "total_tokens": 677, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_68014201e14c8190ac96087406924721", "custom_id": "Celecoxib-Desloratadine-solifenacin-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "f66352ef6ac8adcc96922cac5c1eb85c", "body": {"id": "chatcmpl-BNNppi7Soms5Rh1GngFPv2tuIHp6j", "object": "chat.completion", "created": 1744912865, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient who takes a selective COX-2 inhibiting NSAID primarily prescribed for osteoarthritis and a tricyclic H1 inverse agonist used to treat allergies is at risk for developing cholecystitis. If the same patient instead takes the allergy medication in combination with an oral antimuscarinic agent that manages overactive bladder by reducing bladder contractions, which medication could lead to an increased risk of bursitis when used together with the allergy treatment?\n\nAnswer: solifenacin", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 833, "completion_tokens": 100, "total_tokens": 933, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_cf18407276"}}, "error": null}
{"id": "batch_req_68014201f4048190a6a1dac346688986", "custom_id": "Haloperidol-indometacin-Sildenafil-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "add3679bbbd65a36889900e8b1788cfa", "body": {"id": "chatcmpl-BNNpraVAadjcOYu3pyJKjD9irD89S", "object": "chat.completion", "created": 1744912867, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nWhich drug, characterized by selective inhibition of phosphodiesterase type 5 to enhance nitric oxide-mediated vasodilation for the treatment of erectile dysfunction and pulmonary arterial hypertension, when combined with a nonsteroidal anti-inflammatory agent that acts by inhibiting cyclooxygenase-mediated prostaglandin production, is associated with an increased risk of apoplexy as described by their drug-drug interaction?\n\nAnswer: Sildenafil", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 930, "completion_tokens": 86, "total_tokens": 1016, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680142020854819095f31d93a8649db1", "custom_id": "acetazolamide-Lamotrigine-Metolazone-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "5ccbefc4e564b3faaeeebdee01bcfd07", "body": {"id": "chatcmpl-BNNpsgIPirwAOHykMIfZIcDAFnOs3", "object": "chat.completion", "created": 1744912868, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient with epilepsy and mood stabilization needs is being treated with a medication that functions through inhibition of voltage-sensitive sodium and calcium channels, reducing excitatory neurotransmitter release and carrying risks such as Stevens-Johnson syndrome. If this medication is combined with a thiazide-like diuretic, primarily used for congestive heart failure and hypertension and associated with increased urine volume and decreased bloodstream water absorption, what is the drug that, in combination with the anticonvulsant, may increase the risk of stillbirth?\nAnswer: Metolazone", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 889, "completion_tokens": 111, "total_tokens": 1000, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_680142021ab48190a2145e05e2def0d9", "custom_id": "Ibuprofen-Repaglinide-Perindopril-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "5614a24a893ec1ae364b4afb1216478e", "body": {"id": "chatcmpl-BNNpuVJZCgjdM1kTGqfStPjjTkx5v", "object": "chat.completion", "created": 1744912870, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient with type 2 diabetes who manages their blood sugar using a meglitinide-class agent that stimulates pancreatic insulin secretion develops nasal sinus congestion after introducing a medication that is a long-acting prodrug ACE inhibitor, primarily prescribed for hypertension and heart failure. Which medication was most likely added to the diabetic therapy to cause this specific adverse effect?\n\nAnswer: Perindopril", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 909, "completion_tokens": 77, "total_tokens": 986, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680142022e988190b8ee1610853bd4ca", "custom_id": "Gemfibrozil-Sildenafil-Acamprosate-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "987de55c7b8df594168c288be4309936", "body": {"id": "chatcmpl-BNNpvbIcfKHCtZXefXqux6WnsUE6p", "object": "chat.completion", "created": 1744912871, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient being treated for abnormal blood lipid levels with a fibrate medication is considering using a phosphodiesterase type 5 inhibitor known to enhance nitric oxide-mediated vasodilation. If the use of this vasodilatory agent together with a medication prescribed to reduce cravings in alcoholism may result in loss of weight, which medication for alcohol use disorder is implicated in this interaction?\n\nAnswer: Acamprosate", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 893, "completion_tokens": 83, "total_tokens": 976, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_68014202432481909e29776e239dfe7c", "custom_id": "alendronic acid-Dipyridamole-Sildenafil-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "4af8c07d0b45a73c46bb90dfb8704e7b", "body": {"id": "chatcmpl-BNNpwWNWGidIKl20MAGVmVfnaJpy4", "object": "chat.completion", "created": 1744912872, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient being treated for osteoporosis with an oral bisphosphonate that decreases bone breakdown, who is also prescribed a nucleoside transport inhibitor known for its antiplatelet and vasodilatory effects, is at risk of experiencing erythrema as a side effect of this combination. If, instead, the antiplatelet agent is combined with a selective phosphodiesterase type 5 inhibitor that enhances nitric oxide-mediated vasodilation and is used for erectile dysfunction and pulmonary arterial hypertension, which drug would notably increase the risk of weight gain when taken together with the antiplatelet agent?\n\nAnswer: Sildenafil", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 774, "completion_tokens": 125, "total_tokens": 899, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_6801420255c881909b884b6dd924666f", "custom_id": "Gabapentin-Minoxidil-Perindopril-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "0a9671400227b0c3cbff448328dbe332", "body": {"id": "chatcmpl-BNNpyAhl5BFDu1bIothGikziZ9M8A", "object": "chat.completion", "created": 1744912874, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nWhich medication, characterized by its long-acting inhibition of angiotensin-converting enzyme, hepatic conversion to an active metabolite, and use in managing hypertension and heart failure, has been reported to increase the risk of thrombocytopenia when administered concurrently with a topical or systemic vasodilator commonly used for hair loss and blood pressure reduction?\n\nAnswer: Perindopril", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 808, "completion_tokens": 77, "total_tokens": 885, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_6801420267588190b54b8629c14b5d27", "custom_id": "Famotidine-Ticlopidine-Tirofiban-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "bfb6bf83cf6b6bfe2635f9026d056c95", "body": {"id": "chatcmpl-BNNpzWFjlvDBWi1Uvk4yuRv7Xxjuh", "object": "chat.completion", "created": 1744912875, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient taking an antiplatelet ADP receptor inhibitor, known for its risk of neutropenia and thrombotic microangiopathy, is at increased risk of thrombocytopenia when coadministered with which antiplatelet medication that acts as a glycoprotein IIb/IIIa inhibitor?\n\nAnswer: Tirofiban", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 750, "completion_tokens": 74, "total_tokens": 824, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_680142027bac819080384adb6f2769d0", "custom_id": "Cimetidine-Sumatriptan-Balsalazide-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "2422d3f439cb490548aecd10b08a68f4", "body": {"id": "chatcmpl-BNNq1ocK4XLHuoraO5hXp5oWya8yr", "object": "chat.completion", "created": 1744912877, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nWhich medication, classified as a disease-modifying antirheumatic drug used to treat inflammatory bowel disease by releasing 5-aminosalicylic acid in the large intestine, has been observed to cause difficulty breathing when combined with the triptan-class agent that acts as a selective serotonin 5-HT1B/1D receptor agonist for migraine relief?\n\nAnswer: Balsalazide", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 854, "completion_tokens": 82, "total_tokens": 936, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_cf18407276"}}, "error": null}
{"id": "batch_req_680142028db48190b1616b25de88bbc4", "custom_id": "Ziprasidone-Desloratadine-Telithromycin-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "bd2e12ed6d16a5bc87a5b66d5e8c7c3f", "body": {"id": "chatcmpl-BNNq3RUKu9GbezAuDwSaUfD0d5lUb", "object": "chat.completion", "created": 1744912879, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient who is taking an atypical antipsychotic commonly prescribed for schizophrenia and bipolar disorder, along with a tricyclic H1 inverse agonist used for allergies, experiences increased heart rate. If another medication\u2014specifically a ketolide antibiotic derived from erythromycin, primarily used to treat community-acquired pneumonia\u2014were introduced to this regimen, which drug would be responsible for an increased risk of sinus headache due to an interaction with the allergy medication?\n\nAnswer: Telithromycin", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 799, "completion_tokens": 100, "total_tokens": 899, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
{"id": "batch_req_68014202a1688190a9443bf6815c0248", "custom_id": "Carvedilol-Ibuprofen-Midodrine-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "046551689675791ae52e6290ceef9f60", "body": {"id": "chatcmpl-BNNq40IqSULgSHUwo5NGyagnZDcpt", "object": "chat.completion", "created": 1744912880, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient with chronic heart failure managed by a nonselective beta-adrenergic blocker that also blocks alpha-1 receptors, and experiencing arthralgia, is prescribed a commonly used NSAID for pain relief, both on the WHO Essential Medicines List. If this patient is additionally started on an oral antihypotensive prodrug that acts as a selective alpha-1 agonist for orthostatic hypotension, which of the three agents is most likely to contribute to dry skin due to a drug interaction with the NSAID?\n\nAnswer: Midodrine", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 915, "completion_tokens": 114, "total_tokens": 1029, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_68014202b7c88190901712a1553ead17", "custom_id": "Carvedilol-Dexpramipexole-Trimethoprim-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "fdf758ef1f98e60567c8138306cdbe09", "body": {"id": "chatcmpl-BNNpjTDD6ZdKfPMO0FWHORIH5T1zs", "object": "chat.completion", "created": 1744912859, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nA patient is being considered for a new oral therapy that lowers blood and tissue eosinophils and is specifically in clinical trials for eosinophilic asthma. If this medicine is co-administered with a generic antibiotic used for bladder infections that inhibits bacterial folate metabolism, what drug might contribute to weight gain as a result of their interaction?\n\nAnswer: Trimethoprim", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 829, "completion_tokens": 78, "total_tokens": 907, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_ac00b0000c"}}, "error": null}
{"id": "batch_req_68014202cc1c8190959e558129f60780", "custom_id": "phenytoin-Dapsone-Perindopril-DDI-Bio-1_hop", "response": {"status_code": 200, "request_id": "704b34b1619214bec0b39ad18ec913ba", "body": {"id": "chatcmpl-BNNq6EdvKkeNtsx8zGWbpmQdTh1q3", "object": "chat.completion", "created": 1744912882, "model": "gpt-4.1-2025-04-14", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Question:\nIn a clinical scenario where a bacteriostatic sulfone agent used for leprosy and pneumocystis pneumonia prophylaxis is co-administered with an antihypertensive prodrug that inhibits angiotensin-converting enzyme, what drug, when combined with this antimicrobial, increases the risk of acute kidney failure?\n\nAnswer: Perindopril", "refusal": null, "annotations": []}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 1025, "completion_tokens": 74, "total_tokens": 1099, "prompt_tokens_details": {"cached_tokens": 0, "audio_tokens": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "audio_tokens": 0, "accepted_prediction_tokens": 0, "rejected_prediction_tokens": 0}}, "service_tier": "default", "system_fingerprint": "fp_7439084672"}}, "error": null}
